-- Jiangsu Hengrui Pharmaceuticals' (SHA:600276) unit, Shandong Shengdi Pharmaceutical, obtained approval from China's National Medical Products Administration for the clinical trials of HRS-7156 tablets, according to a Shanghai bourse filing on Thursday.
The drug will be tested as a treatment for heart failure.